Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice

Vaccine

Volumn 30, Issue 40, 2012, Pages 5864-5870

  Kammoun, Hana ^a,b   Feunou, Pascal Feunou ^a,b   Foligne, Benoit ^a,b   Debrie, Anne Sophie ^a,b   Raze, Dominique ^a,b   Mielcarek, Nathalie ^a   Locht, Camille ^a,b  

^a INSERM U1019   (France)

^b UNIV LILLE   (France)

Author keywords

Bordetella bronchiseptica; Bordetella pertussis; Regulatory T cells; Vaccine

Indexed keywords

PERTUSSIS VACCINE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BORDETELLA BRONCHISEPTICA; BORDETELLA BRONCHISEPTICA INFECTION; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IMMUNOPROPHYLAXIS; LUNG PARENCHYMA; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PASSIVE IMMUNIZATION; PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TISSUE INJURY;

ADMINISTRATION, INTRANASAL; ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; BORDETELLA BRONCHISEPTICA; BORDETELLA INFECTIONS; BORDETELLA PERTUSSIS; CYTOKINES; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION; LUNG; MICE; MICE, INBRED BALB C; MICE, SCID; PERTUSSIS VACCINE; PNEUMONIA; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; VACCINES, ATTENUATED;

EID: 84864828274     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.005     Document Type: Article

References (38)

1. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005, 18:326-382.
2. Goodnow R.A. Biology of Bordetella bronchiseptica. Microbiol Rev 1980, 44:722-738.
3. Dugal F., Belanger M., Jacques M. Enhanced adherence of Pasteurella multocida to porcine tracheal rings preinfected with Bordetella bronchiseptica. Can J Vet Res 1992, 56:260-264.
4. Woolfrey B.F., Moody J.A. Human infections associated with Bordetella bronchiseptica. Clin Microbiol Rev 1991, 4:243-255.
5. Dworkin M.S., Sullivan P.S., Buskin S.E., Harrington R.D., Olliffe J., MacArthur R.D., et al. Bordetella bronchiseptica infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1999, 28:1095-1099.
6. Bauwens J.E., Spach D.H., Schacker T.W., Mustafa M.M., Bowden R.A. Bordetella bronchiseptica pneumonia and bacteremia following bone marrow transplantation. J Clin Microbiol 1992, 30:2474-2475.
7. Huebner E.S., Christman B., Dummer S., Tang Y.W., Goodman S. Hospital-acquired Bordetella bronchiseptica infection following hematopoietic stem cell transplantation. J Clin Microbiol 2006, 44:2581-2583.
8. Gueirard P., Weber C., Le Coustumier A., Guiso N. Human Bordetella bronchiseptica infection related to contact with infected animals: persistence of bacteria in host. J Clin Microbiol 1995, 33:2002-2006.
9. Rath B.A., Register K.B., Wall J., Sokol D.M., Van Dyke R.B. Persistent Bordetella bronchiseptica pneumonia in an immunocompetent infant and genetic comparison of clinical isolates with kennel cough vaccine strains. Clin Infect Dis 2008, 46:905-908.
10. de la Torre MJ, de la Fuente CG, de Alegria CR, Del Molino CP, Agüero J, Martinez-Martinez L. Recurrent respiratory infection caused by Bordetella bronchiseptica in an immunocompetent infant. Pediatr Infect Dis J, in press.
11. Stevenson A., Roberts M. Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens. FEMS Immunol Med Microbiol 2003, 37:121-128.
12. Bey R.F., Shade F.J., Goodnow R.A., Johnson R.C. Intranasal vaccination of dogs with liver avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis. Am J Vet Res 1981, 42:1130-1132.
13. de Jong M.F. Prevention of atrophic rhinitis in piglets by means of intranasal administration of a live non-AR-pathogenic Bordetella bronchiseptica vaccine. Vet Q 1987, 9:123-133.
14. Matherne C.M., Steffen E.K., Wagner J.E. Efficacy of commercial vaccines for protecting guinea pigs against Bordetella bronchiseptica pneumonia. Lab Anim Sci 1987, 37:191-194.
15. Ellis J.A., Haines D.M., West K.H., Burr J.H., Dayton A., Townsend H.G., et al. Effect of vaccination on experimental infection with Bordetella bronchiseptica in dogs. J Am Vet Med Assoc 2001, 218:367-375.
16. Gopinathan L., Kirimanjeswara G.S., Wolfe D.N., Kelley M.L., Harvill E.T. Different mechanisms of vaccine-induced and infection-induced immunity to Bordetella bronchiseptica. Microbes Infect 2007, 9:442-448.
17. Goebel E.M., Zhang X., Harvill E.T. Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection. PLoS ONE 2009, 4:e6778.
18. Locht C, Mielcarek N. New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol Med Microbiol, in press.
19. Mielcarek N., Debrie A.S., Raze D., Bertout J., Rouanet C., Younes A.B., et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006, 2:e65.
20. Feunou P.F., Kammoun H., Debrie A.S., Mielcarek N., Locht C. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 2010, 28:7047-7053.
21. Mielcarek N., Debrie A.S., Mahieux S., Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol 2010, 17:317-324.
22. Feunou P.F., Bertout J., Locht C. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS ONE 2010, 5:e10178.
23. Skerry C.M., Mahon B.P. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vaccine Immunol 2011, 18:187-193.
24. Kavanagh H., Noone C., Cahill E., English K., Locht C., Mahon B.P. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin Exp Allergy 2010, 40:933-941.
25. Li R., Lim A., Phoon M.C., Narasaraju T., Ng J.K., Poh W.P., et al. Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm. J Virol 2010, 84:7105-7113.
26. Skerry C.M., Cassidy J.P., English K., Feunou-Feunou P., Locht C., Mahon B.P. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol 2009, 16:1344-1351.
27. Feunou P.F., Ismaili J., Debrie A.S., Huot L., Hot D., Raze D., et al. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 2008, 26:5722-5727.
28. Cotter P.A., Miller J.F. BvgAS-mediated signal transduction: analysis of phase-locked regulatory mutants of Bordetella bronchiseptica in a rabbit model. Infect Immun 1994, 62:3381-3390.
29. Lowenthal J.W., Corthesy P., Tougne C., Lees R., MacDonald H.R., Nabholz M. High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J Immunol 1985, 135:3988-3994.
30. Fedele G., Bianco M., Debrie A.S., Locht C., Ausiello C.M. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J Immunol 2011, 186:5388-5396.
31. Gueirard P., Guiso N. Virulence of Bordetella bronchiseptica: role of adenylate cyclase-hemolysin. Infect Immun 1993, 61:4072-4078.
32. Zhao Z., Xue Y., Wu B., Tang X., Hu R., Xu Y., et al. Subcutaneous vaccination with attenuated Salmonella enterica serovar Choleraesuis C500 expressing recombinant filamentous hemagglutinin and pertactin antigens protects mice against fatal infections with both S. enterica serovar Choleraesuis and Bordetella bronchiseptica. Infect Immun 2008, 76:2157-2163.
33. Harvill E.T., Cotter P.A., Yuk M.H., Miller J.F. Probing the function of Bordetella bronchiseptica adenylate cyclase toxin by manipulating host immunity. Infect Immun 1999, 67:1493-1500.
34. Cohn S.E., Knorr K.L., Gilligan P.H., Smiley M.L., Weber D.J. Pertussis is rare in human immunodeficiency virus disease. Am Rev Respir Dis 1993, 147:411-413.
35. Ho S.Y., Chua S.Q., Foo D.G., Locht C., Chow V.T., Poh C.L., et al. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates. Infect Immun 2008, 76:111-119.
36. Li R., Lim A., Ow S.T., Phoon M.C., Locht C., Chow V.T., et al. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e. Vaccine 2011, 29:5502-5511.
37. McGuirk P., Mills K.H. Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. Eur J Immunol 2000, 30:415-422.
38. Paccani S.R., Finetti F., Davi M., Patrussi L., D'Elios M.M., Ladant D., et al. The Bordetella pertussis adenylate cyclase toxin binds to T cells via LFA-1 and induces its disengagement from the immune synapse. J Exp Med 2011, 208:1317-1330.